Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gadoteridol→

Gadoteridol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
120066-54-8
Molecular formula
C17H29GdN4O7
Molecular weight
558.7 g/mol
Drug class
Gadolinium-based MRI contrast agentmacrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact macrocyclic gadolinium chelate is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast complex, not a therapeutic drug.
Indications / reported uses
  • Contrast enhancement for MRI of the central nervous system in adults and paediatric patients with known or suspected abnormalities; use and age criteria are product-label specific

Sources: US DailyMed — PROHANCE (gadoteridol) · NLM MeSH — Gadoteridol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gadoteridol Environmental Risk Assessment (ERA) (the Gadoteridol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.